MBCP+™

1,990,0002,690,000

Manufacturer: Biomatlante

Origin: France

Package: Option

Clear

MBCP®: Synthetic Bone Graft Substitute Bioactive Calcium Phosphate

Ideally, any biocompatible synthetic bone graft substitute material used to replace or augment graft material should become integrated with the surrounding bone tissue and ultimately be replaced by new healthy bone, as seen with autologous graft.

MBCP® is a biphasic calcium phosphate synthetic bone graft substitute with a unique micro and macroporous structure that most closely resembles to the architecture of natural human bone. Soluble and resorbable, it gradually dissolves in the body, promoting new bone formation through the release of calcium and phosphate ions. In time, the porous structure becomes completely infiltrated with, and replaced by, healthy viable bone.

MBCP® Technology’s Key Features

MBCP+Osteoconductive

Provides a matrix for new bone growth

Molecular mixture of HA and TCP

HA alone resorbs too slowly while TCP resorbs too fast. Bi-phasic HA and TCP allow for a resorption rate similar to that of human bone.

70% porosity, similar to cancellous bone

Interconnected network of macropores and micropores that enables the colonization of bone cells and biological fluid uniformly within the matrix.

Bioactive

For ionic exchange: TCP dissolution and bone crystal precipitation creare newly bioactive interface with bone cells.

Macroporosity

Macropores are a network of interconnected spaces that promote the biological infiltration and cellular colonization by osteoblasts and osteoclasts.

Microporosity

Micropores are the intercrystalline spaces where dissolution and recrystallisation occurs.

>30 years of clinical experience

Host bone formation is demonstrated.

Safe

100% synthetic – 5 years shelf life

Intended use

Orthopaedics and Maxillofacial:

It is intended for use as a bone graft to fill or reconstruct osseous bone defects or gaps of the skeletal system (e.g. extremities, spine and pelvis, dental) that are not intrinsic to the stability of the bone structure. Osseous defects can occur as a result of a trauma or in surgically created defects.
It can be used with autograft as a bone graft extender.

Availability

2 ratios:

  • 60% HA / 40% β-TCP
  • 20% HA / 80% β-TCP*

Granules, Sticks, Wedges, Cylinders, Blocks
Custom-made shapes on request

*granules only

References

[1] Passuti – 1989 – “Macroporous Calcium Phosphate Ceramic Performance in Human Spine Fusion” Clinical Orthopaedics
[2] Rodriguez – 2008 – “Five Years Clinical follow-up Bone Regeneration with CaP bone ceramics” Key Engineering Materials
[3] Kolerman – 2012 – “Clinical Radiographic and Histomorphometrical Analysis of Maxillary Sinus Augmentation using Synthetic Bone Substitute” Journal of Oral and Maxillofacial Surgery
[4] Legeros – 2002 – “Properties of Osteoconductive Biomaterials: Calcium Phosphates” – Clinical Orthopedics
[5] Cavagna – 1999 – “Macroporous Calcium Phosphate Ceramic : a prospective study of 106 cases in Lumbar Spinal Fusion” Journal of Long-Rerm Effects of Medical Implants
[6] Rouvillain – 2009 – “Clinical, radiological and histological evaluation of biphasic calcium phosphate bioceramic wedges filling medial high tibial valgisation osteotomies” The Knee
[7] Ransford – 1998 – “Synthetic porous ceramic compared with autograft in scoliosis surgery 341 patient randomised study” The Journal of Bone and Joint Surgery
[8] Daculsi – 2008 – “Effect of sintering process of HA/TCP bioceramics on microstructure, dissolution, cell proliferation and Bone ingrowth” Key Engineering Materials
[9] Miramond – 2014 – “Comparative critical study of commercial calcium phosphate bone substitutes in terms of physico-chemical properties” – Key Engineering Materials
[10] Duan – 2017 – “Variation of bone forming ability with the physicochemical properties of calcium phosphate bone substitutes” – Article on line
[11] Xie – 2006 – “Evaluation of the osteogenesis and biodegradation of porous biphasic ceramic in the human spine, 20 patients” Biomaterials
[12] Pascal–Mousselard – 2006 – “Anterior Cervical Fusion With PEEK Cages: Clinical Results of a Prospective, Comparative, Multicenter and Randomized Study Comparing Iliac Graft and a Macroporous Biphasic Calcium Phosphate” North American Spine Society
[13] Lavallé – 2004 – “Biphasic Ceramic wedge and plate fixation with locked adjustable screws for open wedge tibial osteotomy” Revue de chirurgie orthopédique
[14] Gouin – 1996 – “Clinical applications of calcium phosphate ceramics” SOFCOT teaching supplement
[15] Gauthier – 1998 – “Macroporous biphasic calcium phosphate ceramics: influence of macropore diameter and macroporosity percentage on bone ingrowth” Biomaterials
[16] Cho – 2011 – “Bioactivity and osteoconductivity of biphasic calcium phosphates” Bioceramics Development and Applications
[17] Nery – 1992 – “Tissue response to biphasic calcium phosphate ceramic with different ratios of HA/TCP in periodontal osseous defects” – Journal of Periodontology
[18] Schaefer – 2011 – “How degradation of calcium phosphate bone substitute materials is influenced by phase composition and porosity” – Advanced Engineering Materials
[19] Daculsi – 2013 – “Clinical studies of anterior cervical fusion with PEEK cages: comparing illiac graft and a Macroporous Biphasic Calcium Phosphate
[20] Legeros – 1988 – “Significance of the porosity and physical chemistry of Calcium Phosphate Ceramics Biodegradation-Bioresorption
[21] Daculsi – 1999 – “Spongious and cortical bone substitution kinetics at the expense of macroporous biphasic calcium phosphate : animal and human evidence” Bioceramics
[22] Changseong – 2014 – “Eight-Year clinical follow-up of sinus grafts with Micro-Macroporous biphasic calcium phosphate granules” Key Engineering Materials
[23] Gouin – 1995 – “Biphasic macroporous calcium phosphate ceramine bone substitute for filling bone defects : a report of 23 cases” Revue de Chirurgie Orthopédique

Precautions

To read the complete precautions, please refer to the Instructions for Use.
The product must only be handled or implanted by trained qualified physicians having read the instructions for use.
MBCP® is intended for use by surgeons familiar with bone grafting and rigid fixation techniques.

Regulatory

  • ISO 13485:2016 MDSAP
  • Read the instructions for use
  • MBCP® is supplied sterile and CE-marked as a Class III Medical Device according to Directive EEC/93/42

Image-logo-CE0123

Disclaimer

Not all products are registered or available in every country/region. Please check with Biomatlante representative for availability and further information.

 

There are no reviews yet.

Related products
In Kone15 glabal D

Implant In-Kone®

Manufacturer: Global D

Origin: France

Package: Box


In Kone16 glabal D

Prosthesis In-Kone®

Manufacturer: Global D

Origin: France

Package: Box


EZ Cure™ Membrane1 biomatlante 1

EZ Cure™ Membrane

Manufacturer: Biomatlante

Origin: France

Package: Option


ULTIMATE Surgical Kit

Manufacturer: Global D

Origin: France

Package: Kit


twinKon 4.7 global D removebg preview

Twinkon® 4

Manufacturer: Global D

Origin: France

Package: Implant/Abutment